Filing Flows › Rigel Pharmaceuticals (RIGL) › Q2 2026
Rigel Pharmaceuticals (RIGL) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Rigel Pharmaceuticals (RIGL) reported revenue of $78.7M for the second quarter 2026 (Q2 2026), -23% from a year earlier and +34% from the quarter before. Operating margin was 30.0%, net earnings $17.3M (22.0% of revenue).
Rigel Pharmaceuticals, Q2 2026: revenue $78.7M (-23% year over year), operating margin 30.0%, net earnings $17.3M, operating cash flow $30.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $78.7M | +34% | -23% |
| Operating profit | $23.6M | +98% | -61% |
| Net earnings | $17.3M | +100% | -71% |
| Operating cash flow | $30.7M | 11× | +0.4% |
What changed
Revenue was $78.7M in Q2 2026, down 23% year over year and up 34% from the previous quarter. Product sales, net was the largest line at 85% of revenue.
Operating profit was $23.6M, a 30.0% margin (down 30.1 points year over year). Total costs grew 36% against a revenue fall of 23%. The fastest-growing cost line was Research & development (+105%). Net earnings were $17.3M, down 71% year over year. The effective tax rate was 26.7%.
Operating cash flow was $30.7M (roughly flat year over year), 177% of net earnings. Non-cash charges added back $848K of depreciation and amortization and $6.8M of share-based compensation. Working capital and other items added $5.7M.
Questions
What was Rigel Pharmaceuticals' revenue in the second quarter 2026?
Rigel Pharmaceuticals (RIGL) reported revenue of $78.7M for the second quarter 2026 (Q2 2026), -23% from a year earlier and +34% from the quarter before.
Was Rigel Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $23.6M (30.0% of revenue) and net earnings $17.3M.